NASDAQ:PIII

P3 Health Partners (PIII) Stock Price, News & Analysis

$0.51
-0.01 (-1.91%)
(As of 04/23/2024 ET)
Today's Range
$0.50
$0.53
50-Day Range
$0.47
$1.16
52-Week Range
$0.45
$5.56
Volume
326,039 shs
Average Volume
302,270 shs
Market Capitalization
$162.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

P3 Health Partners MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
825.9% Upside
$4.75 Price Target
Short Interest
Bearish
4.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.56) to ($0.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.90 out of 5 stars

Medical Sector

800th out of 909 stocks

Health Services Industry

8th out of 10 stocks

PIII stock logo

About P3 Health Partners Stock (NASDAQ:PIII)

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

PIII Stock Price History

PIII Stock News Headlines

The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
P3 Health Partners: Q4 Earnings Insights
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Why Health Management Company P3 Health Partners Shares Are Up Today
P3 Health Partners Inc Class A PIII
55,508
P3 Health Partners Inc - Ordinary Shares - Class A
P3 Health Partners Recent Insider Activity
See More Headlines
Receive PIII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for P3 Health Partners and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/24/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:PIII
Fax
N/A
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$5.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+825.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-57,770,000.00
Pretax Margin
-14.51%

Debt

Sales & Book Value

Annual Sales
$1.27 billion
Cash Flow
$0.10 per share
Book Value
$0.45 per share

Miscellaneous

Free Float
262,010,000
Market Cap
$162.06 million
Optionable
Not Optionable
Beta
1.04
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Sherif Abdou F.A.C.E.P. (Age 63)
    FACP, M.D., Co-Founder, CEO & Director
    Comp: $7.1M
  • Dr. Amir Bacchus M.B.A. (Age 59)
    M.D., Co-Founder, Chief Medical Officer & Director
    Comp: $4.3M
  • Mr. Atul Kavthekar
    CFO & Chief Accounting Officer
  • Mr. William Bettermann
    Executive VP & COO
  • Mr. Devery Goodey
    Senior Vice President of Technology
  • Roy Youngblood
    Director of Compliance
  • Leslie Fisher
    Senior VP of Legal Affairs & General Counsel
  • Ms. Kassi Belz APR
    Executive Vice President of Communications, Culture & Engagement
  • Mr. Todd Lefkowitz MHA
    Chief Managed Care Officer
  • Ms. Sarah Bussmann B.S.N.
    CRNI, M.H.A., R.N., Chief of Staff

PIII Stock Analysis - Frequently Asked Questions

Should I buy or sell P3 Health Partners stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for P3 Health Partners in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PIII shares.
View PIII analyst ratings
or view top-rated stocks.

What is P3 Health Partners' stock price target for 2024?

4 Wall Street research analysts have issued 12 month target prices for P3 Health Partners' shares. Their PIII share price targets range from $4.50 to $5.00. On average, they predict the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 825.9% from the stock's current price.
View analysts price targets for PIII
or view top-rated stocks among Wall Street analysts.

How have PIII shares performed in 2024?

P3 Health Partners' stock was trading at $1.41 on January 1st, 2024. Since then, PIII shares have decreased by 63.6% and is now trading at $0.5130.
View the best growth stocks for 2024 here
.

When is P3 Health Partners' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PIII earnings forecast
.

How were P3 Health Partners' earnings last quarter?

P3 Health Partners Inc. (NASDAQ:PIII) posted its earnings results on Thursday, March, 28th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. The firm had revenue of $346.86 million for the quarter, compared to analyst estimates of $309.80 million. P3 Health Partners had a negative trailing twelve-month return on equity of 120.85% and a negative net margin of 4.56%.

What guidance has P3 Health Partners issued on next quarter's earnings?

P3 Health Partners issued an update on its FY 2024 earnings guidance on Thursday, March, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.4 billion.

How do I buy shares of P3 Health Partners?

Shares of PIII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PIII) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners